Dr. Ross C. Donehower

Dr. Ross C. Donehower is an oncologist in the Baltimore area, caring for patients with gastrointestinal cancers. He was part of the team that developed premedications that allowed paclitaxel — a chemotherapy medication now used to treat several types of cancers — to be safely given to patients. The Virginia and D.K. Ludwig Professor in Clinical Investigation of Cancer, he serves as the director of the Hematology & Medical Oncology Fellowship Program and director of the Division of Medical Oncology at the Johns Hopkins School of Medicine. Dr. Donehower received his undergraduate degree from Hamline University and earned his M.D. from the University of Minnesota. He completed his residency at The Johns Hopkins Hospital. Dr. Donehower joined the Johns Hopkins faculty in 1980. Prior to joining Johns Hopkins, Dr. Donehower was a surgeon with the U.S. Public Health Service and a clinical associate of the medicine branch and clinical pharmacology branch at the National Cancer Institute. His research interests include gastrointestinal cancers, new anticancer drug development and pharmacology. Dr. Donehower serves on the editorial boards of numerous scholarly journals, including the International Journal of Oncology. He has been recognized by the American Society of Clinical Oncology with a 2017 Excellence in Teaching Award. He is a member of several professional organizations, including the American College of Physicians, the American Society of Clinical Oncology and the American Association for Cancer Research.

Dr. Donehower is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Neuroendocrine Tumor, Familial Colorectal Cancer, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.

Dr. Donehower is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 33 peer reviewed articles and participating in 1 clinical trial.